» Authors » Toni Kline

Toni Kline

Explore the profile of Toni Kline including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 432
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng Z, Hom M, Bearrood T, Rosenthal Z, Fernandez D, Ondrus A, et al.
Nat Chem Biol . 2024 Dec; 21(2):309. PMID: 39653787
No abstract available.
2.
Kline T, Xu C, Kreitzer F, Hurst D, Eldeeb K, Wager-Miller J, et al.
Eur J Med Chem . 2023 Jan; 249:115123. PMID: 36708677
The alkylindole (AI), WIN55212-2, modulates the activity of several proteins, including cannabinoid receptors 1 and 2 (CBR, CBR), and at least additional G protein-coupled receptor (GPCR) that remains uncharacterized with...
3.
Li X, Abrahams C, Yu A, Embry M, Henningsen R, DeAlmeida V, et al.
Oncotarget . 2023 Jan; 14:1-13. PMID: 36634212
Overexpression of CD74, a type II transmembrane glycoprotein involved in MHC class II antigen presentation, has been reported in many B-cell non-Hodgkin lymphomas (NHLs) and in multiple myeloma (MM). STRO-001...
4.
Li X, Zhou S, Abrahams C, Krimm S, Smith J, Bajjuri K, et al.
Mol Cancer Ther . 2022 Dec; 22(2):155-167. PMID: 36459691
STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. Here, we describe...
5.
Feng Z, Hom M, Bearrood T, Rosenthal Z, Fernandez D, Ondrus A, et al.
Nat Chem Biol . 2022 Jul; 18(10):1065-1075. PMID: 35788181
Aldehyde dehydrogenases (ALDHs) are promising cancer drug targets, as certain isoforms are required for the survival of stem-like tumor cells. We have discovered selective inhibitors of ALDH1B1, a mitochondrial enzyme...
6.
Abrahams C, Li X, Embry M, Yu A, Krimm S, Krueger S, et al.
Oncotarget . 2019 Feb; 9(102):37700-37714. PMID: 30701025
STRO-001 is a site-specific, predominantly single-species, fully human, aglycosylated anti-CD74 antibody-drug conjugate incorporating a non-cleavable linker-maytansinoid warhead with a drug-antibody ratio of 2 which was produced by a novel cell-free...
7.
Pilkington L, Wagoner J, Kline T, Polyak S, Barker D
J Nat Prod . 2018 Nov; 81(12):2630-2637. PMID: 30485098
1,4-Benzodioxane lignans are a class of bioactive compounds that have received much attention through the years. Herein research pertaining to both 1,4-benzodioxane flavonolignans and 1,4-benzodioxane neolignans is presented. A novel...
8.
Christen M, Kamischke C, Kulasekara H, Olivas K, Kulasekara B, Christen B, et al.
Chembiochem . 2018 Nov; 20(3):394-407. PMID: 30395379
The bacterial second messenger cyclic diguanosine monophosphate (c-di-GMP) is a key regulator of cellular motility, the cell cycle, and biofilm formation with its resultant antibiotic tolerance, which can make chronic...
9.
Almaliti J, Miller B, Pietraszkiewicz H, Glukhov E, Naman C, Kline T, et al.
Eur J Med Chem . 2018 Nov; 161:416-432. PMID: 30384045
Antibody-drug conjugates (ADCs) represent a new dimension of anticancer chemotherapeutics, with warheads to date generally involving either antitubulin or DNA-directed agents to achieve low-to sub-nanomolar potency. However, other potent cytotoxins...
10.
Spangler B, Kline T, Hanson J, Li X, Zhou S, Wells J, et al.
Mol Pharm . 2018 Mar; 15(5):2054-2059. PMID: 29569925
Antibody-drug conjugates (ADCs) are antigen-targeted therapeutics that employ antibodies to deliver potent, cytotoxic effectors to cells with potentially high specificity. While promising clinical results have been achieved, significant pitfalls remain...